AbbVie, Besins must pay $448 million in FTC AndroGel case, judge rules
AbbVie and Besins Healthcare violated antitrust law by filing sham patent litigation to delay the availability of generic AndroGel, a Philadelphia federal judge ruled Friday, ordering the companies to pay $448...To view the full article, register now.
Already a subscriber? Click here to view full article